Experimental peptide combination TAT CARMIL1 reduced collagen degradation as a result of cytokine storm in ex vivo study.
List view / Grid view
Filter the results
The team used cryogenic electron microscopy (cryo-EM) to show how the 10E8 antibody interacts with the HIV’s fusion protein to neutralise the virus.
Researchers have demonstrated that blocking CD47-mediated signalling in mice can enhance the speed of pathogen clearance, presenting a new potential form of immunotherapy.
Dr Sarah Doyle and Dr Ema Ozaki outline their research into SARM1 and why it presents an attractive target for treating retinal degeneration.
Researchers used computational tools to identify regions of the SARS-CoV-2 virus that could potentially provide a safe and long-term immune response.
The team found microglia and CD8 T cells were vital to protecting neurons from vesicular stomatitis virus (VSV) infection and suggest loss of taste and smell in COVID-19 could be due to a certain mechanism of infection.
Pre-clinical testing of the COVIDTRAP™ (STI-4398) protein and STI-1499 antibody reveal they can inhibit SARS-CoV-2 from infecting cells.
Scientists reveal activating tumour suppressor protein TiPARP results in the degradation of several transcription factors implicated in cancer survival.
The loss of retinal light-sensing photoreceptor cells is a leading cause of blindness and the number of individuals affected by retinal degenerative diseases is increasing with an ageing population. Currently, there are no treatments for these diseases and progress in finding new treatments is slow. This article explores the potential…
Non-invasive imaging has played an increasing role in drug discovery and development processes. Nikki Withers spoke with Yochi Slonim, who discusses a novel technology that leverages FRET signals for the discovery of small molecule drugs that selectively control mRNA translation in a novel target space.
Neoantigens have gained much interest in recent years, mainly due to their ability to elicit a strong, specific immune response. Nikki Withers spoke to two immunology experts to explore the progress being made and assess what remains challenging for cancer investigators working on these transformational therapies.
Administering a novel complement protein blocker (B4Crry) alongside reperfusion therapy improved cognitive and motor recovery in a model of ischemic stroke.
Mass spectrometry revealed biomarkers that could be used as drug targets for developing novel therapeutics or to predict whether a patient with COVID-19 will become severely ill.
The novel protocol allows proteins over 100 amino acids long to be synthesised in hours and include amino acids that do not occur in the human proteome.